> Different dementia rating scales may give different results because the study is underpowered for the effect, and/or Aducanumab is only effective in a subset of patients.
Though if a couple thousand people is underpowered for the effect, that's not a great sign for the drug.
Though if a couple thousand people is underpowered for the effect, that's not a great sign for the drug.